Stock Events

Stock Events

Pulmonx 

€1.13
0
+€0.07+6.6% Monday 06:03

Statistics

Day High
1.13
Day Low
1.13
52W High
4.52
52W Low
1.05
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2025
Q1 2026
Next
-0.33
-0.29
-0.25
-0.21
Expected EPS
-0.24037180113
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4NI.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
B2gold
BTG
Mkt Cap5.82B
BTG International's interventional pulmonology portfolio, including devices for lung volume reduction, competes directly with Pulmonx's Zephyr Valves.
Medtronic
MDT
Mkt Cap102.71B
Medtronic offers a range of respiratory and monitoring solutions that can compete with Pulmonx's diagnostic and therapeutic technologies.
Boston Scientific
BSX
Mkt Cap83.97B
Boston Scientific Corporation provides various interventional pulmonology solutions, including airway stents and devices for lung cancer diagnosis and treatment, competing with Pulmonx's offerings.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Ethicon subsidiary, offers products for thoracic surgery and lung health, potentially competing with Pulmonx's lung function improvement solutions.
Koninklijke Philips N.V.
PHG
Mkt Cap24.89B
Philips offers a wide range of respiratory care solutions, including sleep and respiratory care devices, which can indirectly compete with Pulmonx's products.
Smith & Nephew
SNN
Mkt Cap13.3B
Smith & Nephew, with its advanced surgical devices, can compete in the space of lung and thoracic surgery, offering alternatives to Pulmonx's solutions.
Intuitive Surgical
ISRG
Mkt Cap162.13B
Intuitive Surgical's da Vinci robotic surgical systems are used in thoracic procedures, offering a high-tech alternative to traditional and minimally invasive lung surgeries.
Hologic
HOLX
Mkt Cap16.97B
Hologic's imaging and interventional solutions, including those for lung and thoracic applications, offer diagnostic alternatives that can compete with Pulmonx's lung health diagnostics.

About

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Show more...
CEO
Mr. Glendon E. French
Employees
291
Country
United States
ISIN
US7458481014

Listings

STU
DE
4NI.STU
MU
DE
4NI.MU
F
DE
4NI.F
XNAS
US
LUNG

0 Comments

Share your thoughts

FAQ

What is Pulmonx stock price today?▼
The current price of 4NI.MU is €1.13 EUR — it has increased by +6.6% in the past 24 hours. Watch Pulmonx stock price performance more closely on the chart.
What is Pulmonx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pulmonx stocks are traded under the ticker 4NI.MU.
Is Pulmonx stock price growing?▼
4NI.MU stock has risen by +2.73% compared to the previous week, the month change is a +3.67% rise, over the last year Pulmonx has showed a -65.12% decrease.
When is the next Pulmonx earnings date?▼
Pulmonx is going to release the next earnings report on August 05, 2026.
What were Pulmonx earnings last quarter?▼
4NI.MU earnings for the last quarter are -0.28 EUR per share, whereas the estimation was -0.28 EUR resulting in a -1.02% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Pulmonx have?▼
As of May 06, 2026, the company has 291 employees.
In which sector is Pulmonx located?▼
Pulmonx operates in the Health & Wellness sector.
When did Pulmonx complete a stock split?▼
Pulmonx has not had any recent stock splits.
Where is Pulmonx headquartered?▼
Pulmonx is headquartered in Redwood City, United States.